Taysha Gene Therapies annual shareholders’ equity
2020
2021
2022
2023
2024
2025
Taysha Gene Therapies Shareholders’ Equity Growth & History (TSHA)
Taysha Gene Therapies's shareholders’ equity was $246.9M for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $246.9M | $175.4M | +245.25% |
| 2024 | 2024-12-31 | $71.5M | −$3.4M | −4.55% |
| 2023 | 2023-12-31 | $74.9M | $74.0M | +7796.42% |
| 2022 | 2022-12-31 | $949,000 | −$94.4M | −99.01% |
| 2021 | 2021-12-31 | $95.4M | −$155.9M | −62.04% |
| 2020 | 2020-12-31 | $251.3M | — | — |
Taysha Gene Therapies quarterly shareholders’ equity
As of Dec 31, 2019
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $387.3M | $138.5M | +55.70% |
| Q1 2026 | 2026-03-31 | $211.9M | $156.9M | +284.94% |
| Q4 2025 | 2025-12-31 | $246.9M | $175.4M | +245.25% |
| Q3 2025 | 2025-09-30 | $219.0M | $130.2M | +146.62% |
| Q2 2025 | 2025-06-30 | $248.7M | $139.9M | +128.47% |
| Q1 2025 | 2025-03-31 | $55.1M | $1.2M | +2.25% |
| Q4 2024 | 2024-12-31 | $71.5M | −$3.4M | −4.55% |
| Q3 2024 | 2024-09-30 | $88.8M | $137.9M | — |
| Q2 2024 | 2024-06-30 | $108.9M | $146.0M | — |
| Q1 2024 | 2024-03-31 | $53.8M | $68.8M | — |
| Q4 2023 | 2023-12-31 | $74.9M | $74.0M | +7796.42% |
| Q3 2023 | 2023-09-30 | −$49.1M | −$59.8M | — |
| Q2 2023 | 2023-06-30 | −$37.1M | −$69.6M | — |
| Q1 2023 | 2023-03-31 | −$14.9M | −$65.7M | — |
| Q4 2022 | 2022-12-31 | $949,000 | −$94.4M | −99.01% |
| Q3 2022 | 2022-09-30 | $10.7M | −$129.7M | −92.38% |
| Q2 2022 | 2022-06-30 | $32.5M | −$154.0M | −82.57% |
| Q1 2022 | 2022-03-31 | $50.7M | −$172.1M | −77.23% |
| Q4 2021 | 2021-12-31 | $95.4M | −$155.9M | −62.04% |
| Q3 2021 | 2021-09-30 | $140.4M | −$127.2M | −47.54% |
| Q2 2021 | 2021-06-30 | $186.5M | — | — |
| Q1 2021 | 2021-03-31 | $222.9M | — | — |
| Q4 2020 | 2020-12-31 | $251.3M | $251.4M | — |
| Q3 2020 | 2020-09-30 | $267.6M | — | — |
| As of Dec 31, 2019 | 2019-12-31 | −$135,000 | — | — |
Taysha Gene Therapies shareholders’ equity trends
Over the last five fiscal years, Taysha Gene Therapies's shareholders’ equity decreased from $251.3M to $246.9M, a change of −$4.4M. The latest reported quarter, Q2 2026, shows $387.3M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗